Novolog Shortage: A Provider Briefing for 2026

The availability of Novolog (Insulin Aspart) has been a recurring challenge since 2024, and as we move into 2026, the situation demands continued attention from prescribers and healthcare teams. This article provides a comprehensive update on the Novolog supply picture, prescribing implications, cost considerations, and practical tools to help your patients maintain access to rapid-acting insulin.

Timeline of Novolog Supply Disruptions

Understanding the sequence of events helps frame the current situation:

• Q1 2024: Novo Nordisk confirmed backorders for Novolog vials across U.S. distribution channels. FlexPen and FlexTouch presentations were less affected but not immune to spot shortages.
• May 2024: Novo Nordisk resumed shipments of Novolog vials, though supply did not immediately meet full market demand.
• Q3-Q4 2024: Gradual improvement in supply, but regional disparities persisted. Some pharmacies in high-demand areas continued to report stock-outs.
• 2025: Supply largely stabilized for pen presentations. Vial availability remained inconsistent in certain markets.
• December 31, 2025: Novo Nordisk discontinued distribution of its unbranded biologic Insulin Aspart. This product had served as a lower-cost alternative for many patients and pharmacies.
• Q1 2026: Brand Novolog is generally available, but the absorption of former unbranded Insulin Aspart patients into the brand supply has created periodic tightness, particularly for vials.

Prescribing Implications

The evolving supply landscape has several practical implications for prescribers:

Formulary Awareness

With the discontinuation of unbranded Insulin Aspart, patients previously on that product need new prescriptions for brand Novolog or an alternative rapid-acting insulin. Proactively review your patient panels for anyone who may have been affected by this transition.

Presentation Flexibility

When prescribing Novolog, consider specifying that the pharmacy may dispense either vials or pens, depending on availability. If your patient's insurance covers both presentations, this flexibility can prevent delays in filling prescriptions.

Therapeutic Alternatives

When Novolog is unavailable, the following rapid-acting insulins are clinically appropriate alternatives for most patients:

• Humalog (Insulin Lispro): The most commonly used alternative. Similar pharmacokinetic profile. Eli Lilly also offers an authorized generic at lower cost.
• Fiasp (Insulin Aspart): Same active ingredient as Novolog with added niacinamide for faster onset. May be available when standard Novolog is not.
• Admelog (Insulin Lispro): Sanofi's biosimilar to Humalog. Often favored by payers for cost reasons.
• Apidra (Insulin Glulisine): Another rapid-acting option, though less commonly stocked at some pharmacies.

Dose conversion between these agents is generally 1:1, though close glucose monitoring during the first 1-2 weeks of a switch is recommended. Patients using insulin pumps should confirm device compatibility with any new insulin.

Prior Authorization Considerations

Some payer formularies have shifted preferred rapid-acting insulin designations in response to supply changes. Verify current formulary status before prescribing. Many plans have streamlined or waived prior authorization requirements during documented shortage periods — contact the payer directly if your patient encounters access barriers.

Current Availability Picture

As of early 2026:

• Novolog FlexPen and FlexTouch: Generally available at most retail and mail-order pharmacies.
• Novolog Vials: Intermittently available. Some regions and pharmacy chains experience periodic stock-outs.
• Unbranded Insulin Aspart: No longer in distribution as of January 1, 2026.
• Fiasp: Available and may serve as a direct swap for patients who need Insulin Aspart specifically.

For real-time availability data, Medfinder for Providers offers pharmacy-level stock visibility that can help your care team direct patients to locations with confirmed inventory.

Cost and Access Considerations

Affordability remains a critical factor in insulin adherence:

• Novo Nordisk Savings Card: Commercially insured patients may pay as little as $35 per 30-day supply (max savings $65 per fill) or no more than $99 per prescription.
• Medicare Part D: Insulin copays capped at $35/month under the Inflation Reduction Act.
• Novo Nordisk PAP: The Patient Assistance Program provides Novolog at no cost to eligible uninsured patients. Applications available at NovoCare.com or by calling 1-866-310-7549.
• State Copay Caps: Multiple states have enacted insulin copay caps ranging from $25-$100/month for commercial plans.
• Coupon Cards: GoodRx, SingleCare, and other platforms can reduce cash-pay costs to approximately $74-$100 per vial.

For patients experiencing financial hardship, see our provider-focused guide on How to Help Patients Save Money on Novolog.

Tools and Resources for Providers

Several resources can support your practice during supply disruptions:

• Medfinder for Providers: Real-time pharmacy stock lookup to direct patients to available inventory.
• ASHP Drug Shortage Resource Center: Current shortage status and clinical alternatives for Insulin Aspart injection.
• NovoCare HCP Portal: Access savings programs, PAP applications, and patient education materials.
• FDA Drug Shortage Database: Official shortage status updates and manufacturer communications.

Looking Ahead

The insulin market is undergoing significant structural changes. Biosimilar competition continues to expand, and regulatory pathways for interchangeable insulins are maturing. These developments should improve long-term access and affordability, but the transition period may continue to create short-term supply variability.

Key developments to monitor:

• Biosimilar Insulin Aspart approvals and market entry (e.g., Merilog)
• Payer formulary changes favoring lower-cost alternatives
• Expanded $35 insulin cap provisions at state and federal levels
• Novo Nordisk manufacturing capacity investments

Final Thoughts

The Novolog shortage has evolved from an acute crisis in 2024 to a chronic availability challenge in 2026. Proactive prescribing — including formulary awareness, presentation flexibility, and timely alternative selection — can minimize the impact on your patients. Leverage tools like Medfinder for Providers to streamline the process of connecting patients with available inventory.

For a patient-facing version of this update, see Novolog Shortage Update: What Patients Need to Know in 2026.